Hearing improvement after bevacizumab for neurofibromatosis type 2.
Orlando
O
Guntinas-Lichius
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D034381:Hearing Loss / Q000188:drug therapy* / Q000209:etiology; D006320:Hearing Tests / Q000379:methods; D006801:Humans; D016518:Neurofibromatosis 2 / Q000150:complications*; D009464:Neuroma, Acoustic / Q000188:drug therapy* / Q000473:pathology; D012107:Research Design
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab